Click to expand/collapse Jan 06, 2022
Click to open news item in new windowRafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Click to expand/collapse Dec 13, 2021
Click to open news item in new windowRafael Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) From Phase 2 Clinical Trial for Refractory Burkitt Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition

Click to expand/collapse Nov 11, 2021
Click to open news item in new windowRafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

Click to expand/collapse Nov 03, 2021
Click to open news item in new windowEuropean Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma

Click to expand/collapse Oct 28, 2021
Click to open news item in new windowRafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Click to expand/collapse Sep 27, 2021
Click to open news item in new windowRafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.

Click to expand/collapse Aug 26, 2021
Click to open news item in new windowPresident and CEO of Rafael Pharmaceuticals, Sanjeev Luther, to Present at the 11th Annual World Orphan Drug Congress USA 2021

Click to expand/collapse Aug 25, 2021
Click to open news item in new windowRafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Click to expand/collapse Jul 01, 2021
Click to open news item in new windowRafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Click to expand/collapse Jun 30, 2021
Click to open news item in new windowRafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) Congress

   1    2   3   4   5